Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT03861793 Completed - Clinical trials for Advanced Solid Tumors

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Start date: February 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

NCT ID: NCT03853109 Completed - Clinical trials for Advanced Solid Tumors

AMG 404 in Patients With Advanced Solid Tumors

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

NCT ID: NCT03841110 Completed - Colorectal Cancer Clinical Trials

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

NCT ID: NCT03744403 Completed - Clinical trials for Advanced Solid Tumors

A Study of CS1001 in Subjects With Advanced Solid Tumors

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

NCT ID: NCT03733951 Completed - Lymphoma Clinical Trials

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Start date: December 18, 2018
Phase: Phase 1
Study type: Interventional

This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .

NCT ID: NCT03715504 Completed - Clinical trials for Advanced Solid Tumors

Study of TP-3654 in Patients With Advanced Solid Tumors

Start date: April 16, 2019
Phase: Phase 1
Study type: Interventional

TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.

NCT ID: NCT03713905 Completed - Clinical trials for Advanced Solid Tumors

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

NCT ID: NCT03666143 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This was an open-label, multicenter, non-randomized Phase 1b clinical trial for participants with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer (OC), or melanoma.

NCT ID: NCT03588650 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

HLX20
Start date: August 7, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

NCT ID: NCT03577704 Completed - Clinical trials for Advanced Solid Tumors

The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.

HLX07Ib/II
Start date: August 8, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased toxicities.This study is an open-labeled, dose-escalation study designed to explore the maximum tolerated dose (MTD) and safety of HLX07 in combination with different chemotherapy regimens.